RCMI Coordinating Center (RCMI CC) Header Logo

Connection

Kelly DeLong to Cost-Benefit Analysis

Back to Details
This is a "connection" page, showing publications Kelly DeLong has written about Cost-Benefit Analysis.
Kelly DeLong
Connection Strength
0.021
Cost-Benefit Analysis
  1. McGarry LJ, Merchant S, Nathwani D, Pawar V, DeLong K, Thompson D, Akhras K, Ingham M, Weinstein MC. Economic assessment of doripenem versus imipenem in the treatment of ventilator-associated pneumonia. J Med Econ. 2010 Mar; 13(1):142-7.
    View in: PubMed
    Score: 0.021
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support